NCT06942520View on ClinicalTrials.gov

Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)

PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Diabetic Macular Edema
Interventions
GENETIC

RGX-314 Dose 1

AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)

GENETIC

RGX-314 Dose 2

AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)

BIOLOGICAL

Aflibercept (2.0 mg)

Commercially available Active Comparator

Trial Locations (1)

89502

RECRUITING

Sierra Eye Associates, Reno

All Listed Sponsors
collaborator

REGENXBIO Inc.

INDUSTRY

lead

Sierra Eye Associates

OTHER